Fibroid Removal in India
Get Fibroid Removal at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Fibroid Removal in UAE
Fibroid Removal at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Uterine fibroid removal — encompassing myomectomy, hysterectomy, and uterine artery embolization — achieves symptom resolution in 85–95% of appropriately selected patients, restoring quality of life and, in fertility-sparing procedures, preserving reproductive potential. International patients travel to India and the UAE with GAF Healthcare to access world-class gynecological oncology and minimally invasive surgery units at 40–70% below Western costs, with zero compromise on accreditation standards or technology. GAF Healthcare coordinates every clinical and logistical touchpoint — from pre-travel diagnostic review to post-operative fit-to-fly clearance — across its curated network of JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi.
Hospital Stay: 1–4 days (varies by procedure: 1 day for UAE Embolization/HIFU; 2–4 days for robotic or open myomectomy/hysterectomy) • Total Stay in Country (Fit-to-Fly): 1–3 weeks (1 week post-embolization or hysteroscopic resection; 2–3 weeks post-laparoscopic/robotic myomectomy; 3–4 weeks post-open abdominal myomectomy or hysterectomy) • Success Rate: 85–97% (procedure-dependent: hysteroscopic myomectomy 85–90% symptom-free at 2 years; laparoscopic/robotic myomectomy 90–95%; hysterectomy 97–99% definitive cure; UAE 80–90% significant symptom reduction)
What Is It?
Uterine fibroids (leiomyomas) are monoclonal, smooth-muscle tumors of the myometrium driven by estrogen and progesterone receptor overexpression, affecting an estimated 70–80% of women by age 50, with symptomatic disease requiring intervention in 25–50% of cases. Fibroids are classified by FIGO's PALM-COEIN system and by the international FIGO leiomyoma subclassification (Types 0–8) based on anatomical location: submucosal (Types 0–2), intramural (Type 3–5), subserosal (Types 5–7), and cervical or parasitic (Type 8). Clinically significant fibroids cause heavy menstrual bleeding (HMB) leading to iron-deficiency anemia, chronic pelvic pain, dyspareunia, urinary frequency or obstruction from bladder compression, constipation, and infertility or recurrent pregnancy loss — particularly when submucosal distortion of the endometrial cavity is present.
The physiological burden of untreated symptomatic fibroids is substantial: HMB averaging >80 mL blood loss per cycle leads to hemoglobin levels below 10 g/dL in many patients, while bulk symptoms from fibroids exceeding 10 cm can compress the ureters causing hydronephrosis. GnRH agonists (leuprolide) or the newer GnRH antagonist class (relugolix, elagolix) are used preoperatively to shrink fibroid volume by 30–50%, reduce uterine vascularity, and correct anemia — improving surgical safety margins and enabling a minimally invasive approach in patients who might otherwise require laparotomy.
The contemporary standard of care prioritizes fertility-sparing, minimally invasive removal wherever oncologically and anatomically feasible. Hysteroscopic myomectomy remains gold-standard for submucosal fibroids (FIGO 0–1), while robotic-assisted laparoscopic myomectomy (RALM) — platforms including the da Vinci Xi system — has transformed the management of intramural and subserosal fibroids up to 15 cm, offering three-dimensional visualization, articulated instrumentation, and tremor filtration that dramatically reduces blood loss and conversion-to-open rates. For patients with completed families or who decline uterine preservation, total laparoscopic hysterectomy (TLH) provides definitive cure. Uterine artery embolization (UAE) and MRI-guided focused ultrasound surgery (MRgFUS/HIFU) offer non-surgical uterus-preserving alternatives with rapid recovery, though fibroid regrowth rates are higher over a 5-year horizon.
Candidates
• ELIGIBLE PATIENTS:
• Women with symptomatic uterine fibroids confirmed on pelvic ultrasound or MRI (FIGO Classification Types 0–7) causing heavy menstrual bleeding, pelvic pain, bulk symptoms, or reproductive failure
• Patients with submucosal fibroids (FIGO 0–2) distorting the endometrial cavity — primary candidates for hysteroscopic myomectomy
• Women with intramural/subserosal fibroids ≤15 cm and ≤4 fibroids — candidates for robotic-assisted or standard laparoscopic myomectomy
• Patients with fibroids >15 cm, numerous fibroids (>4), or prior multiple abdominal surgeries — candidates for open (abdominal) myomectomy or hysterectomy
• Women who have completed childbearing with symptomatic fibroids — candidates for total laparoscopic hysterectomy (TLH) or total robotic hysterectomy
• Patients wishing to avoid surgery with uterine vascularity confirmed on Doppler imaging — candidates for UAE or MRgFUS/HIFU
• Women with fibroids and secondary iron-deficiency anemia (Hb <10 g/dL) who require preoperative GnRH antagonist therapy (relugolix/elagolix) + iron supplementation before proceeding
• REQUIRED DIAGNOSTIC WORKUP BEFORE ARRIVAL:
• Transvaginal ultrasound (TVUS) or 3D pelvic ultrasound — fibroid mapping (number, size, location per FIGO system)
• Pelvic MRI with contrast — gold-standard for surgical planning; mandatory for fibroids >5 cm, deep intramural fibroids, or suspected adenomyosis co-existence
• Complete Blood Count (CBC), serum ferritin, iron studies — to quantify anemia
• Endometrial biopsy or saline infusion sonohysterography (SIS) — to exclude endometrial hyperplasia or malignancy in women >40 with abnormal bleeding
• CA-125 — if rapidly enlarging fibroids raise concern for leiomyosarcoma (rare, <0.5% of surgical specimens)
• Coagulation profile (PT/APTT), renal and liver function tests
• Cervical cytology (Pap smear) within 3 years
• Echocardiography (ECHO) if patient has cardiac history or pre-operative anemia-related tachycardia
• RELATIVE CONTRAINDICATIONS / CAUTION:
• Suspected uterine leiomyosarcoma on MRI (irregular margins, T2 heterogeneity, rapid growth >1 cm/year) — requires oncology consultation before myomectomy
• Severe coagulopathy uncorrected — increases intraoperative hemorrhage risk
• Active pelvic infection or endometritis — must be treated before elective fibroid surgery
• Contrast allergy or severely impaired renal function (eGFR <30) — limits use of MRI contrast and UAE dye; requires nephrology pre-clearance
• Pedunculated subserosal fibroids on a thin stalk (<2 cm) undergoing UAE — risk of stalk necrosis and peritonitis
• Desire for future pregnancy — UAE and MRgFUS are relatively contraindicated due to risks of uterine necrosis, placentation abnormalities, and unknown long-term fertility data; myomectomy preferred
• Postmenopausal status — new or enlarging fibroids post-menopause require exclusion of malignancy before any ablative procedure
Procedure
HYSTEROSCOPIC MYOMECTOMY (FIGO Type 0–2 Submucosal Fibroids) Performed under general or spinal anesthesia via the natural vaginal canal — no incisions. A rigid hysteroscope with a resectoscope loop (monopolar or bipolar energy — the latter preferred to reduce fluid absorption risk) or the MyoSure tissue removal device is introduced transcervically. Fibroids up to 4–5 cm are resected in a single session; larger type 1–2 fibroids may require a two-stage approach. Distension media monitoring (fluid deficit limits: <1,000 mL bipolar, <750 mL monopolar) is mandatory. Operative time: 30–60 minutes. Same-day or overnight discharge. Menstrual improvement in 85–90% at 12 months.
ROBOTIC-ASSISTED LAPAROSCOPIC MYOMECTOMY — RALM (Primary advanced approach for intramural/subserosal fibroids) The da Vinci Xi robotic system provides 10× 3D magnification, EndoWrist articulation (7 degrees of freedom), and tremor filtration — critical advantages for precise myometrial incision, enucleation, and layered closure (2–3 layer uterine reconstruction with barbed suture, e.g., V-Loc) that reduces the risk of uterine rupture in subsequent pregnancies. Four port sites (5–12 mm). Intraoperative vasopressin injection into the myometrium reduces blood loss. Cell-saver autotransfusion may be used. Closed power morcellation is avoided; specimen extraction uses a mini-laparotomy port extender or endoscopic bag to prevent dissemination. Suitable for fibroids up to 15 cm and up to 4–6 fibroids in experienced hands. Hospital stay: 1–2 days. Return to normal activity: 2–3 weeks.
STANDARD LAPAROSCOPIC MYOMECTOMY Equivalent oncologic and fertility outcomes to RALM in centers without robotic capability; technically demanding for deep intramural fibroids requiring multi-layer suturing. Blood loss and conversion-to-laparotomy rates are slightly higher than robotic in comparative studies. Still the preferred approach in high-volume centers in India and the UAE where robotic access is not available for all cases.
OPEN (ABDOMINAL) MYOMECTOMY — LAPAROTOMY Reserved for: very large uteri (>16–18 weeks gestational size), fibroids >15 cm, >6–8 fibroids, or anatomy precluding laparoscopic access. Pfannenstiel (bikini line) or midline incision. Vasopressin + tourniquet techniques minimize blood loss. Cell-saver autotransfusion routinely used. Hospital stay: 3–5 days. Full recovery: 4–6 weeks. Still clinically appropriate for complex cases.
TOTAL LAPAROSCOPIC HYSTERECTOMY (TLH) — Definitive Cure For women with completed families. Removal of uterus (and optionally cervix — total vs. supracervical) laparoscopically using LigaSure, Harmonic scalpel, or advanced bipolar vessel-sealing technology. Uterine specimen extracted vaginally or via culdotomy. No abdominal incisions >12 mm. Hospital stay: 1–2 days. Recovery: 2–3 weeks. Recurrence rate: 0% (definitive). Cervical cytology must be current before choosing supracervical approach.
TOTAL ROBOTIC HYSTERECTOMY (TRH) Robotic platform provides precision advantage particularly in cases with obesity, deep endometriosis coexistence, or adhesions from prior surgery. Outcomes equivalent to TLH; marginally longer operating time but reduced conversion rate.
UTERINE ARTERY EMBOLIZATION (UAE / UFE) Interventional radiology (non-surgical) procedure performed under conscious sedation. Bilateral femoral or radial artery access; selective catheterization of uterine arteries under fluoroscopy; embolization using calibrated microspheres (500–700 μm or 700–900 μm Embosphere/PVA particles) to devascularize fibroid tissue. Post-embolization syndrome (fever, cramping, nausea) managed with NSAIDs and anti-emetics for 48–72 hours. Fibroid infarction confirmed on MRI at 3 months. Symptom improvement in 80–90%; fibroid volume reduction 40–60% at 6 months. Fibroid regrowth rate 20–25% at 5 years. Not recommended if future fertility is desired.
MRI-GUIDED FOCUSED ULTRASOUND SURGERY (MRgFUS / HIFU) Fully non-invasive, outpatient procedure requiring no anesthesia. High-intensity focused ultrasound energy delivered transcutaneously under real-time MRI thermometry guidance causes coagulative necrosis of fibroid tissue (ExAblate 2100 or Sonalleve platform). Best suited for a small number of accessible, non-calcified, T2-hypointense fibroids ≤10 cm. FDA-cleared. Fibroid non-perfused volume (NPV) ratio >80% correlates with durable symptom relief. Not suitable for fibroids adjacent to bowel or sacrum, or with intervening bowel loops. Recovery: same-day discharge, return to work in 1–3 days.
PREOPERATIVE MEDICAL OPTIMIZATION GnRH antagonists (relugolix 40 mg/day PO or elagolix 300 mg BID) — 8–12 week preoperative course shrinks fibroid volume 30–50% and corrects HMB-related anemia, enabling minimally invasive surgery in borderline candidates. Superior to GnRH agonists (leuprolide) due to oral dosing, rapid onset, and absence of initial flare effect. Intravenous iron infusion (ferric carboxymaltose or low-molecular-weight iron dextran) corrects anemia within 2–4 weeks, avoiding allogenic blood transfusion.
Cost of Fibroid Removal: India vs. UAE
The cost of fibroid removal varies significantly depending on the surgical approach chosen — from hysteroscopic resection for small submucosal fibroids through to robotic-assisted myomectomy or total laparoscopic hysterectomy for complex cases. Both India and the UAE offer internationally accredited centers with world-class surgical teams at a fraction of Western healthcare costs, but India consistently offers the lowest absolute pricing — typically 40–65% below equivalent UAE costs — while the UAE commands a premium for its luxury hospital infrastructure, multilingual care teams, and geographic convenience for patients traveling from Europe, Africa, and the GCC. All estimates below cover surgical fees, anesthesia, hospital stay, standard medications, and routine diagnostics; robotic surgery surcharges, blood products, and extended ICU stays are billed additionally.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $1,500 – $6,000 | ~58% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $4,000 – $14,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-TRAVEL CONSULTATION (2–4 weeks before departure)
• Submit diagnostic reports (MRI pelvis with contrast, ultrasound, CBC, CA-125, coagulation profile, Pap smear) to GAF Healthcare's clinical team via secure portal
• Remote multidisciplinary tumor board review by gynecological surgeon and, if UAE considered, interventional radiologist — treatment recommendation issued within 48 hours
• Surgeon's virtual consultation scheduled (video call): procedure selection confirmed, risks and fertility implications discussed, consent process initiated
• If preoperative GnRH antagonist therapy is indicated, prescription issued and therapy started in home country 8–12 weeks prior to surgery date
• GAF Healthcare issues treatment authorization letter, visa assistance documents, and cost breakdown
PHASE 2 — ARRIVAL AND PRE-OPERATIVE ASSESSMENT (Day 1–2)
• Airport pick-up by GAF Healthcare case manager; transfer to partner accommodation or hospital
• Day 1: Pre-admission workup at hospital — repeat CBC, coagulation studies, ECG, anesthesia consultation, bowel prep (if open surgery planned)
• Day 2 morning: Admission to hospital; IV access established; pre-operative antibiotics (cefazolin 2g IV) administered 30–60 minutes before incision; DVT prophylaxis initiated (LMWH + TED stockings); surgical site skin preparation
• Anesthesia type confirmed: general anesthesia (GA) for laparoscopic/robotic/open cases; spinal ± light sedation for hysteroscopic; conscious sedation for UAE
PHASE 3 — THE PROCEDURE (Day 2)
• Hysteroscopic myomectomy: 30–60 minutes; recovery room 2–4 hours; discharge same day or next morning
• Laparoscopic/robotic myomectomy: 90–180 minutes; recovery room 2 hours; ward admission for 1–2 nights
• Open myomectomy / hysterectomy: 90–150 minutes; ICU or HDU monitoring for first night; ward for 2–3 additional days
• UAE: 45–90 minutes interventional radiology suite; 24-hour admission for pain management post-embolization
• MRgFUS: 2–4 hours outpatient; same-day discharge
• Intraoperative cell-saver used for open and complex laparoscopic cases; vasopressin injection standard for myomectomy
PHASE 4 — IN-HOSPITAL RECOVERY (Days 2–5 depending on procedure)
• Pain management: IV ketorolac + paracetamol multimodal protocol; opioids reserved for breakthrough pain
• Early mobilization: sitting upright on Day 1 post-op; ambulating on Day 1–2 (laparoscopic/robotic cases)
• Urinary catheter removed at 24 hours (laparoscopic); 48 hours (open)
• Diet: clear liquids Day 1; soft diet Day 2; regular diet by Day 3
• Discharge criteria: stable vitals, pain controlled on oral analgesia, tolerating diet, normal urine output, wound check
• Discharge medications: oral analgesics (ibuprofen 400mg TDS + paracetamol), iron supplementation, proton pump inhibitor, LMWH for 10–14 days post-discharge (extended VTE prophylaxis per ERAS guidelines)
PHASE 5 — POST-DISCHARGE RECOVERY IN DESTINATION COUNTRY (Days 5–21)
• GAF Healthcare case manager conducts daily WhatsApp check-ins for first 7 days
• Day 7: Wound review at outpatient clinic; staples/clips removed if open surgery
• Day 10–14: Surgeon review; fit-to-fly assessment conducted (criteria: afebrile, hemodynamically stable, no wound complications, DVT risk acceptable, no peritoneal signs)
• Hysteroscopic / UAE / MRgFUS: Fit to fly Day 5–7
• Laparoscopic/robotic myomectomy: Fit to fly Day 10–14
• Open myomectomy / hysterectomy: Fit to fly Day 18–21
• Compression stockings and LMWH mandatory during long-haul flights >4 hours
PHASE 6 — HOME RECOVERY AND FOLLOW-UP
• Week 2–4: Light activities; avoid lifting >5 kg; no intercourse for 6–8 weeks (myomectomy) or 8 weeks (hysterectomy)
• Week 4–6: Return to desk work (laparoscopic); Week 6–8 (open cases)
• Month 3: Follow-up pelvic ultrasound or MRI — fibroid clearance confirmed; uterine cavity assessment in fertility patients
• Month 6: Fertility consultation if pregnancy desired (recommended to wait 3–6 months post-myomectomy before conception, 12 months after open myomectomy with deep uterine incision)
• GAF Healthcare telemedicine follow-up at 6 weeks, 3 months, and 12 months post-procedure
Risks & Considerations
Fibroid removal is a well-established gynecological procedure with an excellent safety profile in experienced hands, but patients must be counseled on procedure-specific risks as part of informed consent. For hysteroscopic myomectomy, the principal risks include uterine perforation (0.5–1.5%), fluid overload/hyponatremia from distension media absorption (managed by strict deficit monitoring), cervical laceration, and intrauterine adhesion (Asherman's syndrome) formation, particularly with aggressive resection of the posterior wall or in cases with multiple submucosal fibroids. For laparoscopic and robotic myomectomy, intraoperative hemorrhage requiring conversion to open surgery occurs in 2–8% of cases (higher with large or multiple fibroids); injury to adjacent structures (ureter, bowel, bladder) is rare but recognized (<1%); and the adequacy of uterine wall closure determines the risk of uterine rupture in a subsequent pregnancy (estimated 0.5–1% with well-constructed multilayer closure). For open myomectomy, risks include wound infection, ileus, adhesion formation causing future infertility or bowel obstruction, and a longer VTE window. For uterine artery embolization, post-embolization syndrome (fever, pain, malaise lasting 3–10 days) is expected and managed supportively; premature ovarian failure is reported in 1–2% of cases (higher in women over 45), and inadvertent non-target embolization of ovarian or gluteal vessels is rare but serious. A critical oncologic risk across all procedures is unrecognized leiomyosarcoma — present in fewer than 0.5% of surgical fibroid specimens but associated with poor prognosis if disseminated by morcellation; all centers in the GAF Healthcare network adhere to contained bag-extraction protocols and do not perform uncontained power morcellation. Fibroid recurrence after myomectomy is a recognized phenomenon, with cumulative 5-year recurrence rates of 10–27% depending on fibroid number, size, and patient age; GnRH antagonist maintenance therapy and progesterone-releasing IUD post-procedure may reduce recurrence risk. Hysterectomy eliminates recurrence entirely and is the only truly curative intervention. All patients receive extended LMWH thromboprophylaxis per ERAS-Gynecology guidelines for 10–28 days post-discharge to mitigate deep vein thrombosis and pulmonary embolism risk — a critical safety measure for international patients undertaking long-haul return flights.
Top Hospitals for Fibroid Removal
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Aster Hospital Dubai
Dubai, UAE
Top Doctors for Fibroid Removal
Internationally trained specialists in Gynecology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Tarang Preet Kaur
MBBS, MS, MRCOG, MCh, Fellowship in Urogynaecology, Fellowship in Cosmetic Gynaecology
Urogynaecologist
Max Super Speciality Hospital, Saket, New Delhi, India
11+ Yearsof experience
Dr. Tarang Preet Kaur is a Consultant in Urogynaecology with over 11 years of clinical experience, currently practicing at Max Super Speciality Hospital, Saket in New Delhi. She holds an MCh in Urogynaecology from Edge Hill University, United Kingdom (2024), the MRCOG from the Royal College of Obstetricians & Gynaecologists, and an MS in Obstetrics & Gynaecology from Maulana Azad Medical College, Delhi. Her dual qualification across India and the UK… Read more
Dr. Amrinder Kaur Bajaj
MBBS, MD — Obstetrics & Gynaecology (Gold Medalist), Senior Residency — Obstetrics & Gynaecology, FRSH — Fellow of the Royal Society of Health, FIAMS — Fellow of the Indian Association of Medical Specialists
Obstetrician & Gynaecologist
Fortis Hospital, Gurgaon, Gurgaon, India
42+ Yearsof experience
Dr. Amrinder Kaur Bajaj is one of Delhi-NCR's most experienced gynaecologists, with over four decades spent caring for women at every stage of life. She currently practises as a Consultant in Obstetrics & Gynaecology at Fortis Hospital, Gurgaon, where she brings together deep clinical knowledge and a quietly reassuring bedside manner that patients — and their families — find genuinely comforting. Her academic journey set a high bar early on. She completed… Read more
Dr. Anuradha Khurana
MBBS, DGO (Diploma in Obstetrics & Gynaecology), PG in High Risk Pregnancy and Infertility
Gynecologist & Obstetrics Specialist
Artemis Hospital, New Delhi, India
20+ Yearsof experience
Dr. Anuradha Khurana is a Senior Consultant in Obstetrics and Gynecology at Artemis Hospital, Delhi, with over two decades of hands-on experience in women's health. She is particularly well regarded for her work in high-risk pregnancy management, uterine conditions like fibroids and endometriosis, and complex gynecological surgeries. Patients and families consistently describe her as someone who takes the time to truly listen — and to explain things in a… Read more
Dr. Aswari Kesari Kapoor
MBBS, DGO (Diploma in Gynaecology & Obstetrics), CPS (College of Physicians and Surgeons), DNB (Diplomate of National Board) — Obstetrics & Gynaecology
Obstetrician & Gynecologist
Indraprastha Apollo Hospital, New Delhi, India
23+ Yearsof experience
Dr. Aswari Kesari Kapoor is a seasoned Obstetrician and Gynecologist with over 23 years of hands-on clinical experience. She practices at Indraprastha Apollo Hospital in New Delhi — one of India's most respected multi-specialty institutions. Over the course of her career, she has built a strong reputation for managing complex gynecological conditions alongside high-risk pregnancies, all with a calm and reassuring bedside manner that patients consistently… Read more
Dr. Bindhu K S
MBBS, DNB (Obstetrics & Gynecology), Fellowship in Minimal Access Surgery, FICOG (Fellowship of the Indian College of Obstetricians and Gynaecologists), Certificate in Gynecologic and Obstetric Sonography, Certificate in Appreciation of Well Being in Fetal Heart Disease
Obstetrician & Gynecologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
23+ Yearsof experience
Dr. Bindhu K S is a seasoned Obstetrician and Gynecologist based in Mumbai, currently practicing at Apollo Hospitals, Navi Mumbai. With over two decades of clinical experience, she brings together expertise in both obstetrics and advanced minimally invasive gynecologic surgery. Whether a patient comes with a complex fibroid, troublesome endometriosis, or a high-risk pregnancy, Dr. Bindhu approaches each situation with careful thought and genuine care. Her… Read more
Frequently Asked Questions — Fibroid Removal
The cost of fibroid removal varies by procedure type and destination. In India, costs range from approximately USD 1,500 to USD 6,000 — covering hysteroscopic myomectomy at the lower end (USD 1,500–2,500), laparoscopic or robotic-assisted myomectomy in the mid-range (USD 2,500–4,500), and open abdominal myomectomy or total laparoscopic hysterectomy at the upper end (USD 3,500–6,000). Uterine artery embolization in India is typically USD 1,800–3,500. In the UAE (Dubai or Abu Dhabi), the same procedures cost considerably more due to the premium hospital infrastructure and higher operating costs: hysteroscopic myomectomy USD 4,000–6,000; laparoscopic/robotic myomectomy USD 6,000–10,000; open myomectomy or hysterectomy USD 8,000–14,000; UAE embolization USD 5,000–9,000. India is typically 40–65% less expensive than the UAE for equivalent surgical outcomes, with both destinations offering JCI-accredited hospitals and internationally trained surgeons. These estimates include surgery, anesthesia, hospital stay, and standard medications; robotic platform surcharges, blood products, prolonged ICU care, or complications are billed separately. GAF Healthcare provides a transparent, itemized cost estimate for your specific fibroid profile before any financial commitment is made.
The minimum safe stay before an international flight depends entirely on the surgical approach used. For hysteroscopic myomectomy (no abdominal incisions), patients are typically fit to fly in 5–7 days. For uterine artery embolization (UAE) and MRI-guided focused ultrasound (MRgFUS), fit-to-fly is generally 5–7 days after the post-procedure pain management period resolves. For laparoscopic or robotic-assisted myomectomy, we advise a minimum 10–14 days in-country before flying, as this allows time for wound healing, exclusion of early post-operative complications (hematoma, infection, ileus), and a formal fit-to-fly review by your surgeon. For open abdominal myomectomy or total laparoscopic hysterectomy, a minimum 18–21 days in-country is recommended before long-haul flight travel. The rationale is multifactorial: immobility during long flights significantly increases deep vein thrombosis (DVT) and pulmonary embolism risk in the post-operative period; all patients flying home must wear graduated compression stockings and continue low-molecular-weight heparin (LMWH) injections for the duration of the flight and 5–10 days post-arrival as per international VTE prophylaxis guidelines. GAF Healthcare's treating surgeon issues a formal fit-to-fly certificate before your departure date is confirmed, and travel insurance documentation is coordinated to reflect the approved travel window.
Success rates for fibroid removal are high but vary by procedure type and how 'success' is defined — whether as symptom relief, fibroid clearance, or fertility outcomes. Hysteroscopic myomectomy for submucosal fibroids achieves heavy menstrual bleeding resolution in 80–90% of patients at 24 months, with a fibroid regrowth or re-intervention rate of 10–15% over 5 years. Laparoscopic and robotic-assisted myomectomy achieve 90–95% major symptom resolution, with cumulative fibroid recurrence rates of 10–27% at 5 years depending on fibroid number and size (single fibroid <5 cm has the lowest recurrence). In fertility-seeking patients, clinical pregnancy rates after laparoscopic myomectomy for infertility-related fibroids are 40–60%, particularly when submucosal distortion is corrected. Open abdominal myomectomy carries similar recurrence rates to laparoscopic approaches but allows treatment of the most complex fibroid burdens. Total laparoscopic or robotic hysterectomy is the only procedure with a 97–99% definitive cure rate and zero fibroid recurrence, as the uterus is removed entirely; it is appropriate only for women with completed families. Uterine artery embolization achieves significant symptom improvement in 80–90% of patients at 12 months, with fibroid volume reduction of 40–60%, but 20–25% of patients require additional intervention within 5 years due to fibroid regrowth or inadequate response. MRgFUS achieves durable symptom control in approximately 70–80% of carefully selected patients at 12 months. All procedures at GAF Healthcare's partner hospitals are performed by fellowship-trained minimally invasive gynecological surgeons with individual case volumes exceeding 200 fibroid surgeries per year, which is independently associated with lower complication rates and superior oncologic and reproductive outcomes.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare manages the complete non-clinical infrastructure of your medical journey to India or the UAE, so that every hour of your time abroad is focused on recovery rather than administration.
VISA AND ENTRY DOCUMENTATION: For India: GAF Healthcare's visa support team prepares and submits your e-Medical Visa (e-MV) application to the Indian government's online portal, including the mandatory hospital sponsorship letter from the treating facility. The e-Medical Visa permits a 60-day stay, extendable, and allows up to two attendants to travel on an e-Medical Attendant Visa simultaneously. Standard processing time is 3–5 business days; expedited processing available. For the UAE (Dubai/Abu Dhabi): Citizens of 50+ countries including the UK, EU, USA, Canada, Australia, and GCC nations receive visa-free entry or visa-on-arrival for 30–90 days — no pre-arranged medical visa required. Citizens of other nationalities receive a medical tourism visa letter from GAF Healthcare's UAE partner hospitals, facilitating a single-entry tourist or medical visa. The UAE's multicultural, English-Arabic bilingual healthcare environment means minimal language barriers for most international patients.
AIRPORT AND GROUND TRANSFERS: Private air-conditioned vehicle meets you at the arrivals gate at all major hubs — Indira Gandhi International (DEL), Chhatrapati Shivaji Maharaj International (BOM), Kempegowda International (BLR), Rajiv Gandhi International (HYD), Dubai International (DXB), and Abu Dhabi International (AUH). Post-operative transfers are in wheelchair-accessible vehicles with a trained medical escort where required.
DEDICATED CASE MANAGERS AND TRANSLATORS: Every patient is assigned a named GAF Healthcare Case Manager — a medically trained coordinator who accompanies you (physically or via WhatsApp/phone) from arrival to departure. Language interpreters are provided at no additional charge for Arabic, Russian, French, Swahili, Amharic, and Bengali-speaking patients in both India and the UAE. All hospital documentation — surgical consent forms, discharge summaries, operative notes — is translated and couriered to your home physician.
ATTENDANT AND ACCOMMODATION SERVICES: Companion accommodation is arranged adjacent to the hospital — partner guesthouses in India (typically USD 25–60/night) or serviced apartments in Dubai/Abu Dhabi (USD 80–180/night). For patients requiring extended stays post-discharge, GAF Healthcare negotiates weekly rates with vetted recovery-friendly apartments offering proximity to the hospital for outpatient wound checks and physiotherapy sessions. Dietary needs including halal, vegan, and culturally specific meals are confirmed in advance with accommodation providers.
POST-DISCHARGE TELEMEDICINE: All GAF Healthcare patients receive a 12-month telemedicine follow-up package — scheduled consultations with the treating surgeon at 6 weeks, 3 months, and 12 months via secure video call. Imaging reports from your home country can be uploaded and reviewed by the India/UAE team at any point during recovery.